GSK’s TYKERB Receives Accelerated Approval For First-Line Combination Treatment Of Metastatic Breast Cancer
GlaxoSmithKline announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for a new combination regimen using TYKERB (lapatinib) as a first- line, all-oral treatment for women with metastatic breast cancer. Source: General Cancer News Articles Provided by Cancer Compass
